Home > Opioid use disorder (OUD). Opioid agonist therapy.

Institut national d'excellence en sante et en services sociaux. (2021) Opioid use disorder (OUD). Opioid agonist therapy. Quebec: INESSS.

[img]
Preview
PDF (Opioid use disorder (OUD). Opioid agonist therapy)
487kB
[img]
Preview
PDF (Efficacy and safety of buprenorphine and methadone for the treatment of opioid use disorder: English summary)
1MB
[img]
Preview
PDF (Oral opioid agonists for the treatment of opioid use disorder: English summary)
1MB

The illicit use and misuse of opioids increase the risk of developing opioid use disorder (OUD), impair one’s well-being and increase the risk of fatal overdose. Providing treatment using a harm reduction approach means mitigating the negative consequences of opioid use rather than eliminating the behaviour at all costs, in order to maximize treatment retention.

Opioid use disorder (OUD) is associated with high rates of mortality and morbidity. Methadone and the sublingual formulation of buprenorphine-naloxone are the two main opioid agonists indicated by Health Canada for the treatment of OUD. Although methadone has been used for this indication for over 40 years, its use raises certain questions regarding quality of life and safety for those being treated, particularly because of its high number of interactions with other medications and possible QT interval prolongation. Buprenorphine, on the other hand, is a partial opioid agonist that produces a plateau effect which appears to decrease the risk of overdose and adverse effects (e.g., cardiac arrhythmia), as well as withdrawal symptoms when the treatment is discontinued. A systematic review of the available scientific data was conducted in order to take a position regarding the preferred pharmacological treatment options for opioid use disorder while developing an optimal use guide on oral opioid agonists for the treatment of OUD (Summary PDF provided above)

Item Type
Report
Publication Type
International, Guideline, Manual, Report
Drug Type
Opioid
Intervention Type
Drug therapy, Treatment method
Date
May 2021
Pages
8 p.
Publisher
INESSS
Corporate Creators
Institut national d'excellence en sante et en services sociaux
Place of Publication
Quebec
Notes
This optimal usage guide is provided for information purposes only and should not replace the professional’s judgment. The recommendations in this guide concern individuals with opioid use disorder, whether the opioids are obtained by prescription or illicitly. The recommendations were developed using a systematic process and are supported by the scientific literature and by the knowledge and experience of Québec clinicians and experts.
EndNote
Related (external) link

Repository Staff Only: item control page